The effect of PCSK9 Inhibitor EVOLOCUMAB on aldosterone among high cardiovascular risk patients

2020 ◽  
Author(s):  
Elena Lzkhakov ◽  
Yakov Shacham ◽  
Mariana Yaron ◽  
Merav Serebro ◽  
Karen Tordjman ◽  
...  
Keyword(s):  
Cardiovascular Risk ◽  
High Cardiovascular Risk ◽  
Pcsk9 Inhibitor ◽  
Risk Patients

Telmisartan in High Cardiovascular Risk Patients

2012 ◽  
Vol 8 (1) ◽  
pp. 10 ◽  
Author(s):  
Roland Asmar ◽  
Keyword(s):  
Cardiovascular Disease ◽  
Cardiovascular Risk ◽  
Ace Inhibitors ◽  
Angiotensin Receptor Blockers ◽  
High Cardiovascular Risk ◽  
Raas Blockade ◽  
Risk Patients ◽  
Receptor Blockers ◽  
Current Guidelines

The worldwide morbidity and mortality burden of cardiovascular disease (CVD) is overwhelming and caused by increasing life expectancy and an epidemic of risk factors, including hypertension. Therapeutic options targeting different areas of the renin–angiotensin–aldosterone system (RAAS) to disrupt pathophysiological processes along the cardiovascular continuum are available. Angiotensin-converting enzyme (ACE) inhibitors are first-line treatments for CVD and angiotensin receptor blockers (ARBs) are suitable alternatives. Both ACE inhibitors and ARBs prevent CVD by lowering blood pressure (BP). Additionally, several studies have demonstrated that RAAS blockade can reduce cardiovascular risk beyond what might be expected from BP lowering alone. However, the ARBs are not all equally effective. Telmisartan is a long-lasting ARB that effectively controls BP over the full 24-hour period. Recently, the Ongoing telmisartan alone and in combination with ramipril global endpoint trial (ONTARGET) study showed that telmisartan reduces cardiovascular events in high cardiovascular risk patients similarly to the gold standard ACE inhibitor ramipril beyond BP lowering alone, but with a better tolerability. Based on the results of the ONTARGET and Telmisartan randomized assessment study in ACE intolerant subjects with cardiovascular disease (TRANSCEND) studies, telmisartan is indicated for the reduction of cardiovascular morbidity. This article aims to review current guidelines for the management of CVD and consider key data from clinical trials and clinical practice evaluating the role of telmisartan in CVD.

Use of Left Ventricular Strain to Predict Heart Failure and Mortality in High Cardiovascular Risk Patients

2018 ◽  
Vol 27 ◽  
pp. S285-S286
Author(s):  
K. Haji ◽  
T. Marwick ◽  
C. Neil ◽  
S. Stewart ◽  
M. Carington ◽  
...  
Keyword(s):  
Heart Failure ◽  
Cardiovascular Risk ◽  
Left Ventricular ◽  
High Cardiovascular Risk ◽  
Left Ventricular Strain ◽  
Risk Patients

scholarly journals Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patients: The ODYSSEY OPTIONS II randomized trial

2016 ◽  
Vol 244 ◽  
pp. 138-146 ◽  
Author(s):  
Michel Farnier ◽  
Peter Jones ◽  
Randall Severance ◽  
Maurizio Averna ◽  
Elisabeth Steinhagen-Thiessen ◽  
...  
Keyword(s):  
Cardiovascular Risk ◽  
Randomized Trial ◽  
Efficacy And Safety ◽  
High Cardiovascular Risk ◽  
Risk Patients

scholarly journals Experience of the use of the PCSK9 inhibitor Alirocumab in patients with extremely high cardiovascular risk

Kardiologiia ◽  
2020 ◽  
Vol 60 (8) ◽  
pp. 71-77
Author(s):  
V. A. Korneva ◽  
T. Yu. Kuznetsova ◽  
I. S. Scopetc ◽  
N. N. Vezikova
Keyword(s):  
Acute Coronary Syndrome ◽  
Cardiovascular Risk ◽  
Cerebrovascular Disease ◽  
Laboratory Data ◽  
Myocardial Revascularization ◽  
Real Life ◽  
Transient Ischemic Attacks ◽  
High Cardiovascular Risk ◽  
Pcsk9 Inhibitor ◽  
Coronary Syndrome

Aim To study the efficacy and safety of alirocumab in patients with high and very high cardiovascular risk in the Republic of Karelia and to evaluate their compliance with the alirocumab therapy.Materials and methods Study design: observational, noncomparative. The observation group consisted of 9 patients receiving alirocumab (Praluent®) (mean age, 48.6±4.7 years; 7 men). 7 patients had familial hypercholesterolemia of the type diagnosed by DLCN criteria; five patients had MI. Lipid profile, concentrations of transaminases, creatinine, glucose, and lipoprotein a (LP(a)) were measured at 3, 6, 12, and 18 months. Electrocardiography was performed, and the clinical picture (development of acute coronary syndrome, acute cerebrovascular disease, transient ischemic attacks, myocardial revascularization, and cardiovascular death) was evaluated. Efficacy criteria included the absence of these clinical conditions, the proportion of patients who achieved the LDL CS goal, and the decrease in LP(a). Safety was evaluated by clinical and laboratory data, such as levels of transaminases, total bilirubin, creatinine, and blood glucose. The observation lasted for 6 months to 1.5 years.Results LDL CS goals were achieved in 7 (77.8%) patients receiving alirocumab. The mean level of LP(a) decreased from 0.39 to 0.28 g/l; the degree of decrease ranged from 20 to 33 %. No cases of IHD instability (acute coronary syndrome) or new cases of acute cerebrovascular disease and transient ischemic attacks were observed. None of the patients had to stop the alirocumab treatment; adverse effects, including local ones, were not observed.Conclusion LDL CS goals were achieved in 7 (77.8%) patients. The level of LP(a) decreased by 20-33% in patients receiving the PCSK9 inhibitor. In real-life clinical practice, the alirocumab treatment was characterized with high compliance and good tolerability without side effects, including local ones.

Real-World Characteristics And Risk Of Cardiovascular Events In High Cardiovascular Risk Patients In France

2019 ◽  
Vol 287 ◽  
pp. e180
Author(s):  
G. Désaméricq ◽  
F. Fagnani ◽  
C. Emery ◽  
J. Gourmelen ◽  
J.V. Chauny ◽  
...  
Keyword(s):  
Cardiovascular Risk ◽  
Real World ◽  
Cardiovascular Events ◽  
High Cardiovascular Risk ◽  
Risk Patients

scholarly journals Body mass index, cognitive deficit and depressive symptoms in high cardiovascular risk patients

2010 ◽  
Vol 4 (4) ◽  
pp. 313-319 ◽  
Author(s):  
Amanda Lucas da Costa ◽  
Juliana Santos Varela ◽  
Matheus Roriz Cruz ◽  
Andry Fitterman Costa ◽  
Paulo Dornelles Picon ◽  
...  
Keyword(s):  
Cognitive Impairment ◽  
Depressive Symptoms ◽  
Cardiovascular Risk ◽  
Geriatric Depression Scale ◽  
Depression Scale ◽  
Obese Patients ◽  
High Cardiovascular Risk ◽  
Point Increase ◽  
Risk Patients ◽  
Relationship Of

Abstract To evaluate the relationship of obesity, cognitive impairment and depressive symptoms in patients with high cardiovascular risk. Methods: A sample of 93 patients aged 50 years or older was selected from the Center of Dyslipidemia and High Cardiovascular Risk from Hospital de Clínicas de Porto Alegre (HCPA). Patients with stroke were excluded. For cognitive evaluation, the MMSE (Mini Mental State Examination) was used. A score of 24 or less was considered as cognitive impairment, and for those who had 4 years or less of education, the cutoff point was 17. The GDS-15 (Geriatric Depression Scale) was also used, with the cutoff of 6 for presence of depressive symptoms. Results: Obese patients showed lower mean MMSE scores compared to non-obese patients (p=0.0012). Additionally, for every one point increase in BMI above 30 there was a 27% increase in the chances of the patient having cognitive impairment. The obese patients presented 31% chance of having cognitive impairment compared with overweight subjects. Conclusions: Our findings corroborated the association between obesity and cognitive impairment in high cardiovascular risk patients. This association however, was not observed for depressive symptoms.

W08-P-028 B-type natriuretic peptide and endothelin in high cardiovascular risk patients without target-organ damage

2005 ◽  
Vol 6 (1) ◽  
pp. 36-37
Author(s):  
J. Saban-Ruiz ◽  
E. Bernal ◽  
O. Sanchez ◽  
J. Masquez ◽  
B. Monge ◽  
...  
Keyword(s):  
Cardiovascular Risk ◽  
Natriuretic Peptide ◽  
Target Organ Damage ◽  
Organ Damage ◽  
Target Organ ◽  
High Cardiovascular Risk ◽  
Risk Patients

Flavonoid-rich grapeseed extracts: a new approach in high cardiovascular risk patients?

2006 ◽  
Vol 60 (11) ◽  
pp. 1484-1492 ◽  
Author(s):  
P. KAR ◽  
D. LAIGHT ◽  
K. M. SHAW ◽  
M. H. CUMMINGS
Keyword(s):  
Cardiovascular Risk ◽  
High Cardiovascular Risk ◽  
New Approach ◽  
Risk Patients
Sign in / Sign up

Export Citation Format

Share Document